Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma

Hematology Reports

Volumn 4, Issue 2, 2012, Pages

  Salmenniemi, Urpu ^a   Remes, Kari ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Hemolytic uremic syndrome; Multiple myeloma; Thrombotic thrombocytopenic purpura

Indexed keywords

EID: 84887211986     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2012.e13     Document Type: Article

References (7)

1. Franchini M, Zaffanello M, Veneri D. Advances in the pathogenesis, diagnosis and treatment of thrombotic thrombocy¬topenic purpura and haemolytic uremic syndrome. Thromb Res 2006;118:117-84.
2. Dlott JS, Danielson CFM, Blue-Hnidy DE, et al. Drug-induced thrombotic thrombocy¬topenic purpura/haemolytic uremic syn¬drome: A concise review. Ther Apher Dial 2004;8:102-11.
3. Alonso JV, Fonseca J, Lopera E, et al. A report of disseminated adenocarcinoma presenting as thrombotic thrombocytopenic purpura. Hematology Reports 2011;3:e14.
4. Choi MK, Hong JY, Jang JH, et al. TTP-HUS associated with sunitinib. Cancer Res Treat 2008;40:211-3.
5. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358: 1129-36.
6. Karin M, Cao Y, Greten FR, et al. NF-KB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
7. Morito R, Hashino S, Shirai S, et al. Thrombotic microangiopathy after treat¬ment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 2008;88:248-50.